Repaglinide Patent Expiration
Repaglinide is used for improving glycemic control in adults with type 2 diabetes mellitus. It was first introduced by Gemini Laboratories Llc
Repaglinide Patents
Given below is the list of patents protecting Repaglinide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Prandin | US6677358 | NIDDM regimen |
Jun 12, 2018
(Expired) | Gemini Labs Llc |
Repaglinide's Family Patents
Explore Our Curated Drug Screens
Repaglinide Generic API Manufacturers
Several generic applications have been filed for Repaglinide. The first generic version for Repaglinide was by Sun Pharmaceutical Industries Inc and was approved on Jul 11, 2013. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Mar 22, 2023.
Given below is the list of companies who have filed for Repaglinide generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS TOTOWA
Actavis Totowa Llc has filed for 3 different strengths of generic version for Repaglinide. Given below are the details of the strengths of this generic introduced by Actavis Totowa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Discontinued | ORAL | N/A | Jan 22, 2014 |
| 1MG | tablet | Discontinued | ORAL | N/A | Jan 22, 2014 |
| 2MG | tablet | Discontinued | ORAL | N/A | Jan 22, 2014 |
Manufacturing Plant Locations New
Actavis Totowa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Actavis Totowa as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
2. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 3 different strengths of generic version for Repaglinide. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Prescription | ORAL | AB | Jan 22, 2014 |
| 1MG | tablet | Prescription | ORAL | AB | Jan 22, 2014 |
| 2MG
(reference standard) | tablet | Prescription | ORAL | AB | Jan 22, 2014 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
3. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 3 different strengths of generic version for Repaglinide. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Prescription | ORAL | AB | Nov 22, 2013 |
| 1MG | tablet | Prescription | ORAL | AB | Jan 22, 2014 |
| 2MG | tablet | Prescription | ORAL | AB | Jan 22, 2014 |
4. KENTON
Kenton Chemicals And Pharmaceuticals Corp has filed for 3 different strengths of generic version for Repaglinide. Given below are the details of the strengths of this generic introduced by Kenton.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Discontinued | ORAL | N/A | Apr 24, 2015 |
| 2MG | tablet | Discontinued | ORAL | N/A | Apr 24, 2015 |
| 0.5MG | tablet | Discontinued | ORAL | N/A | Apr 24, 2015 |
Manufacturing Plant Locations New
Kenton's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Kenton as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
5. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 3 different strengths of generic version for Repaglinide. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Prescription | ORAL | AB | Mar 22, 2023 |
| 1MG | tablet | Prescription | ORAL | AB | Mar 22, 2023 |
| 2MG | tablet | Prescription | ORAL | AB | Mar 22, 2023 |
6. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 3 different strengths of generic version for Repaglinide. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Discontinued | ORAL | N/A | Aug 23, 2013 |
| 2MG | tablet | Discontinued | ORAL | N/A | Jan 22, 2014 |
| 1MG | tablet | Discontinued | ORAL | N/A | Jan 22, 2014 |
7. PADAGIS US
Padagis Us Llc has filed for 3 different strengths of generic version for Repaglinide. Given below are the details of the strengths of this generic introduced by Padagis Us.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.5MG | tablet | Prescription | ORAL | AB | Jul 17, 2013 |
| 1MG | tablet | Prescription | ORAL | AB | Jan 22, 2014 |
| 2MG | tablet | Prescription | ORAL | AB | Jan 22, 2014 |
Manufacturing Plant Locations New
Padagis Us's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Padagis Us as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
8. SUN PHARM INDS INC
Sun Pharmaceutical Industries Inc has filed for 2 different strengths of generic version for Repaglinide. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Discontinued | ORAL | N/A | Jul 11, 2013 |
| 2MG | tablet | Discontinued | ORAL | N/A | Jul 11, 2013 |